Geser Felix, Wenning Gregor K, Poewe Werner, McKeith Ian
Clinical Department of Neurology, Medical University Innsbruck, Austria.
Mov Disord. 2005 Aug;20 Suppl 12:S11-20. doi: 10.1002/mds.20535.
Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia in older people that has only been recognized in the past decade and that remains widely underdiagnosed. At postmortem examination, affected patients show numerous alpha-synuclein-positive Lewy bodies (LB) in many parts of the cerebral cortex, particularly neocortical and limbic areas in addition to the nigral LB degeneration characteristic of Parkinson's disease (PD). Clinical presentation, unlike PD, is with progressive cognitive decline with particular deficits of visuospatial ability as well as frontal executive function accompanied by usually only mildly to moderately severe parkinsonism, which is often akineto-rigid without the classical parkinsonian rest-tremor. Further accompanying features include spontaneous recurrent visual hallucinations and conspicuous fluctuations in alertness and cognitive performance. The two main differential diagnoses are Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). To improve the differential diagnosis of DLB, consensus criteria have been developed that establish possible and probable levels of clinical diagnostic accuracy. Generally, their sensitivity is variable and low but their specificity is high. Current consensus is to restrict a diagnosis of DLB only to patients with parkinsonism who develop dementia within 12 months of the onset of motor symptoms. Using operationalized criteria, DLB can be diagnosed clinically with an accuracy similar to that achieved for AD or PD. Ancillary investigations, particularly neuroimaging, can aid in differential diagnosis. We review the present state of the best practice in the clinical diagnosis of DLB. Future modifications of diagnostic criteria would ideally include the full range of clinical presentations that can be associated with LB disease.
路易体痴呆(DLB)是老年人神经退行性痴呆的第二大常见病因,在过去十年才被认识到,目前仍普遍存在诊断不足的情况。尸检时,受影响的患者在大脑皮质的许多部位,特别是新皮质和边缘系统区域,除了具有帕金森病(PD)特征性的黑质路易体(LB)变性外,还显示出大量α-突触核蛋白阳性的路易体(LB)。与PD不同,其临床表现为进行性认知衰退,尤其存在视觉空间能力以及额叶执行功能的特定缺陷,并伴有通常仅为轻度至中度严重的帕金森综合征,往往是运动不能-强直型,而无典型的帕金森静止性震颤。其他伴随特征包括反复出现的视幻觉以及警觉性和认知表现的明显波动。两个主要的鉴别诊断是阿尔茨海默病(AD)和帕金森病痴呆(PDD)。为了改善DLB的鉴别诊断,已制定了共识标准,确立了临床诊断准确性的可能和很可能水平。一般来说,它们的敏感性变化不定且较低,但特异性较高。目前的共识是,仅将DLB诊断限于在运动症状出现后12个月内发生痴呆的帕金森综合征患者。使用操作性标准,DLB在临床上的诊断准确性与AD或PD相似。辅助检查,尤其是神经影像学检查,有助于鉴别诊断。我们回顾了DLB临床诊断的最佳实践现状。理想情况下,未来诊断标准的修订应涵盖与LB病相关的所有临床表现。